VIRAL REBOUND DURING AND AFTER SARS-CoV-2 TREATMENT

ABSTRACT

SARS-CoV-2 viral rebound after treatment with nirmatrelvir-ritonavir is an area of ongoing concern for both patients and providers. However, viral rebound has been described both during and after treatment with other antiviral therapies as well. It also appears that viral and symptom rebound can occur in the absence of antiviral therapy, especially in the immunosuppressed patient population. In this presentation, we will review the pathogenesis and risk factors for viral rebound during and after SARS-CoV-2 treatment. We will also explore the clinical and transmission risk of viral rebound and potential management strategies.